+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Nivolumab Market 2021-2025

  • ID: 5317073
  • Report
  • April 2021
  • Region: China
  • China Research & Intelligence

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Medarex
  • Ono Pharmaceuticals
  • MORE
Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma. Nivolumab was first developed by Medarex and Ono Pharmaceuticals. In 2009, Bristol-Myers Squibb acquired these two companies and obtained the patent for Nivolumab. Nivolumab was launched in China in 2018. By 2020, Bristol-Myers Squibb Pharma EEIG is the only manufacturer in the Chinese Nivolumab market.

According to this market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020. The growth rate in 2020 was 52.2%, which slowed down due to the COVID-19 epidemic. The CAGR of Nivolumab’s sales values in China is 108.7% from 2018 to 2020.

The analyst analyzes that as the epidemic situation has been improved and the hospitals resume their operation, sales of Nivolumab will have a recovery growth from 2021 to 2025. Besides, sales will also increase due to market expansion. Currently, Nivolumab has three approved indications, including non-small cell lung cancer, head and neck squamous cell carcinoma, and gastric adenocarcinoma and gastroesophageal junction cancer. Its fourth indication application is at the approval stage. As the number of approved indications increases, sales will continue to grow. On the other hand, the usage rate of Nivolumab was lower than that of other PD-1 products that have been included in the national medical insurance catalog. If the medical insurance negotiation for Nivolumab succeeds, the price adjustment can reduce the burden on patients, which will increase its usage rate.

Topics Covered:

  • The impact of COVID-19 on China's Nivolumab market
  • Sales value and volume of China's Nivolumab 2016-2020
  • Competitive landscape of China's Nivolumab market
  • Prices of Nivolumab in China
  • Prices of Nivolumab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Nivolumab market
  • Prospect of China's Nivolumab market from 2021 to 2025
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Medarex
  • Ono Pharmaceuticals
  • MORE
1 Relevant Concepts of Nivolumab
1.1 Indications for Nivolumab
1.2 Development of Nivolumab in China
1.3 Governmental Approval of Nivolumab in China
1.4 The Impact of COVID-19 on Nivolumab sales in China

2 Sales of Nivolumab in China, 2018-2020
2.1 Sales Value of Nivolumab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Nivolumab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Nivolumab by Dosage Form in China, 2018-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Nivolumab Manufacturers in China, 2018-2020
3.1 Analysis of Market Share of Major Nivolumab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Bristol-Myers Squibb Pharma EEIG
3.2.1 Enterprise Profile
3.2.2 Sales of OPDIVO (BMS’ Nivolumab) in China

4 Prices of Nivolumab for Different Manufacturers in China, 2020-2021
4.1 Bristol-Myers Squibb Pharma EEIG (OPDIVO)

5 Prospect of Chinese Nivolumab drug Market, 2021-2025
5.1 Influential Factors of Chinese Nivolumab Market Development
5.1.1 The Impact of COVID-19 on Chinese Nivolumab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Nivolumab Injection Registration in China
Chart Sales Value of Nivolumab Injection over the World
Chart Sales Value of Nivolumab Injection in China, 2018-2020
Chart Sales Value of Nivolumab Injection in China by Regions, 2018-2020
Chart Sales Volume of Nivolumab Injection in China, 2018-2020
Chart Sales Volume of Nivolumab Injection in China by Regions, 2018-2020
Chart Market Share by Sales Value of Top Nivolumab Manufacturers in China, 2018-2020
Chart Sales Value and Volume of OPDIVO in China, 2018-2020
Chart Referential Prices of OPDIVO in China, 2020-2021
Chart Forecast on Sales Value of Nivolumab in China, 2021-2025
Chart Forecast on Sales Volume of Nivolumab in China, 2021-2025
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Bristol-Myers Squibb 
  • Medarex 
  • Ono Pharmaceuticals
Note: Product cover images may vary from those shown

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll